Viela Bio

$53.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.28 (+0.53%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Viela Bio and other stocks, options, and ETFs commission-free!

About VIE

Viela Bio, Inc. Common Stock, also called Viela Bio, is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. The listed name for VIE is Viela Bio, Inc. Common Stock.

CEO
Zheng Bin Yao
Employees
139
Headquarters
Gaithersburg, Maryland
Founded
2017
Market Cap
2.92B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.02M
High Today
$53.83
Low Today
$52.95
Open Price
$53.05
Volume
773.19K
52 Week High
$70.66
52 Week Low
$25.02

VIE Earnings

-$1.09
-$0.73
-$0.36
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Mar 1, After Hours

You May Also Like

FCOR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure